<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413048</url>
  </required_header>
  <id_info>
    <org_study_id>1001AGCVSP3</org_study_id>
    <nct_id>NCT01413048</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension</brief_title>
  <official_title>Phase III Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient With Stage 1 to 2 Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in
      patient with stage 1 to 2 essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is 2,8 weeks, multi-center, randomized, double-blind, active clinical trial to
      evaluate the efficacy and safety of AGSCT101 versus Carvedilol in patient with stage 1 to 2
      essential hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in diastolic blood pressure (DBP)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure (DBP)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure (SBP)</measure>
    <time_frame>2, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who reach overall blood pressure control (defined as BP &lt;140/90)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>AGSCT101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 25mg</intervention_name>
    <description>Tablet, q.d.</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSCT101 12.5mg</intervention_name>
    <description>Tablet, q.d.</description>
    <arm_group_label>AGSCT101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients â‰¥ 19 years of age

          -  Mild to moderate essential hypertension: sDBP 90 ~ 109, sSBP 140 ~ 179

          -  Subjects who agree to participate in this sudy and give written informed consent

          -  Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

        Exclusion Criteria:

          -  The sitting DBP is more than 110mmHg or the sitting SBP over 180mmHg

          -  Patients with postural hypotension

          -  Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological
             or hepatic(AST, ALT more 3 times more than upper limit of normal)disease

          -  Female of childbearing potential who does not undergo hysterectomy or is not
             post-menopausal

          -  Patients judged to have a history of alcohol or drug abuse by the investigator

          -  Patients with a history of myocardial infarction, severe coronary artery disease or
             clinically significant heart failure or valvular defect in last 6 months

          -  Patients with uncontrolled diabetes mellitus

          -  Patients participated other clinical trial 12 weeks before Screening Patients judged
             to be inappropriate for this study by the investigator with other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki-Bae Seung, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea-St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hun-Sik Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Gyu Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moo-Yong Rhee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongguk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Ju Choi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-Jea Tahk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung-Han Yoon, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Ha Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Ho Jeong, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Wook Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Young Yoon, Manager</last_name>
    <phone>+82-2-3289-4257</phone>
    <email>syyoon@ahn-gook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea-St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-bae Seung, Professor</last_name>
      <phone>+82-2-2258-1148</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Woohyuk Jeong/Senior Researcher</name_title>
    <organization>Project Planning and Development Team</organization>
  </responsible_party>
  <keyword>Essential Hypertension</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

